WHO ICTRP trial
Phase I psilocybin safety trial
ISRCTN15259909 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN15259909 |
|---|---|
| Public title | Phase I psilocybin safety trial |
| Scientific title | A Phase I study to assess the safety of psilocybin when administered to healthy participants enrolled in a psychedelic-assisted therapy training program |
| Primary sponsor | ATMA Journey Centers Inc. |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase I |
| Countries | Canada |
| Conditions | Documenting psilocybin safety in healthy participants Not Applicable |
| Interventions | 25 mg of oral psilocybin, with a duration of effects lasting 4-6 hours. |
| Registration date | Dec 4, 2023 |
| Target size | 20 |
| Secondary IDs | Nil known;Nil known;ATMA0001 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: